The stock of Xilio Therapeutics Inc (NASDAQ: XLO) has increased by 8.64 when compared to last closing price of 0.96.Despite this, the company has seen a gain of 5.04% in its stock price over the last five trading days. globenewswire.com reported 2024-11-07 that Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically “cold” tumors
Is It Worth Investing in Xilio Therapeutics Inc (NASDAQ: XLO) Right Now?
The stock has a 36-month beta value of -0.28. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for XLO is 20.53M, and at present, short sellers hold a 1.93% of that float. On November 18, 2024, the average trading volume of XLO was 246.30K shares.
XLO’s Market Performance
The stock of Xilio Therapeutics Inc (XLO) has seen a 5.04% increase in the past week, with a 31.65% rise in the past month, and a 13.06% gain in the past quarter. The volatility ratio for the week is 17.30%, and the volatility levels for the past 30 days are at 16.35% for XLO. The simple moving average for the past 20 days is -4.26% for XLO’s stock, with a 12.06% simple moving average for the past 200 days.
Analysts’ Opinion of XLO
Many brokerage firms have already submitted their reports for XLO stocks, with Chardan Capital Markets repeating the rating for XLO by listing it as a “Buy.” The predicted price for XLO in the upcoming period, according to Chardan Capital Markets is $7 based on the research report published on December 21, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XLO reach a price target of $36. The rating they have provided for XLO stocks is “Buy” according to the report published on January 10th, 2022.
Raymond James gave a rating of “Outperform” to XLO, setting the target price at $31 in the report published on November 16th of the previous year.
XLO Trading at 14.98% from the 50-Day Moving Average
After a stumble in the market that brought XLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.11% of loss for the given period.
Volatility was left at 16.35%, however, over the last 30 days, the volatility rate increased by 17.30%, as shares surge +33.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.91% upper at present.
During the last 5 trading sessions, XLO rose by +5.04%, which changed the moving average for the period of 200-days by +55.22% in comparison to the 20-day moving average, which settled at $1.0863. In addition, Xilio Therapeutics Inc saw 89.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XLO starting from GILEAD SCIENCES, INC., who purchase 485,250 shares at the price of $0.76 back on Apr 02 ’24. After this action, GILEAD SCIENCES, INC. now owns 7,345,473 shares of Xilio Therapeutics Inc, valued at $368,790 using the latest closing price.
Atlas Venture Fund XI, L.P., the 10% Owner of Xilio Therapeutics Inc, sale 733 shares at $0.64 during a trade that took place back on Feb 08 ’24, which means that Atlas Venture Fund XI, L.P. is holding 2,019,563 shares at $469 based on the most recent closing price.
Stock Fundamentals for XLO
Current profitability levels for the company are sitting at:
- -8.52 for the present operating margin
- 0.82 for the gross margin
The net margin for Xilio Therapeutics Inc stands at -8.35. The total capital return value is set at -1.75. Equity return is now at value -170.96, with -82.36 for asset returns.
Currently, EBITDA for the company is -73.8 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of -0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
To sum up, Xilio Therapeutics Inc (XLO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
